CBER’s Marks Says US FDA’s Rare Disease Work Expected To Win Trump Administration Support

 
• By Sue Sutter
  
Windsock
The FDA's Peter Marks hopes the support for rare disease drug development continues. (Shutterstock)

More from Cell & Gene Therapies

More from Rare Diseases